Field & Main Bank raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 6.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 15,165 shares of the biopharmaceutical company’s stock after purchasing an additional 980 shares during the period. Field & Main Bank’s holdings in Bristol-Myers Squibb were worth $891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors have also made changes to their positions in BMY. W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $101,000. Institutional & Family Asset Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $106,000. Centerpoint Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 373.1% in the 1st quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 1,399 shares in the last quarter. Landaas & Co. WI ADV acquired a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at $131,000. Finally, Mount Yale Investment Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $179,000. 72.17% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently commented on BMY. SunTrust Banks restated a “buy” rating and issued a $67.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, July 31st. UBS Group downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 target price on the stock. in a research note on Monday, May 21st. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Saturday, July 14th. BMO Capital Markets boosted their target price on shares of Bristol-Myers Squibb from $47.00 to $51.00 and gave the company a “market perform” rating in a research note on Monday, July 23rd. Finally, Credit Suisse Group boosted their target price on shares of Bristol-Myers Squibb from $58.00 to $61.00 and gave the company a “neutral” rating in a research note on Friday, July 27th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb has an average rating of “Hold” and a consensus target price of $63.11.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 26th. The biopharmaceutical company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The business had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.48 billion. Bristol-Myers Squibb had a net margin of 1.74% and a return on equity of 42.58%. The firm’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 EPS. sell-side analysts forecast that Bristol-Myers Squibb Co will post 3.62 earnings per share for the current fiscal year.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Read More: Trading Strategy Examples and Plans
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.